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Case presentation
A 58-year-old white man was transferred to University Hospital for
hypokalemia and refractory hypertension. Hypertension, first noted 10
years prior to admission, was treated with a variety of medications,
including diuretics. Several weeks before admission the blood pressure
was 220/120 mm Hg and the serum potassium was 2.5 mEq/liter.
Diuretic therapy was stopped, and 80 mEq/day of potassium chloride
failed to raise the plasma potassium level after one week. The plasma
renin level measured on a random sample was not detectable, and the
supine plasma aldosterone level was 41 ng/dl.
At the time of admission the blood pressure was 190/126 mm Hg, and
the heart rate was 66 beats/mm. Funduscopic examination revealed
mild arteriolar narrowing; the remainder of the physical examination
was within normal limits. The laboratory data disclosed: hematocrit,
55%; sodium, 140 mEq/Iiter; potassium, 2.8 mEq/liter; chloride, 99
mEq/liter; bicarbonate, 35 mEq/liter; BUN, 16 mg/dl; serum creatinine,
1.1 mg/dl; and calcium, 10.7 mg/dl. Microscopic evaluation of the urine
sediment showed only occasional red cells per high-power field.
The plasma renin activity was less than 0.1 ng/ml/hr not only in the
supine and erect positions, but also after administration of furosemide.
Aldosterone secretion rate was 319 sg/day (normal range, 50 to 150 tg/
day); the urinary tetrahydroaldosterone excretion was 236 and 208 zg/
day on 2 days (normal less than 85 pg/day.) Plasma aldosterone levels
fell from 25 ng/dl to 19.5 ng/dI after furosemide administration. Plasma
18-hydroxy-corticosterone levels were 109 ng/dl at 8 AM and 105 ng/dl at
12 noon (both markedly elevated).
An abdominal CT scan showed no definite lesion. An iodocholesterol
scan done after dexamethasone administration revealed mild predom-
inance of uptake in the right adrenal gland. Adrenal vein catheterization
yielded the following results: venous aldosterone concentration was
1235 ng/dl in the right adrenal vein and 30 ng/dl in the left adrenal vein.
Correct positioning of the catheter was confirmed by ACTH-stimulated
cortisol levels.
During the subsequent 4 weeks, the patient was treated with 20 mg of
amiloride daily. The serum potassium rose to normal, and hypertension
was ameliorated. The patient subsequently underwent a right adrenal-
ectomy through a right posterior flank incision. The postoperative
course was complicated by a right flank hematoma, a complication
possibly related to the previous adrenal vein catheterization. The
hypokalemia resolved after the first postoperative week, but the blood
pressure continued to be labile into the third postoperative week. By
the final week of hospitalization, excellent blood pressure control was
achieved with small doses of clonidine. The patient has remained
normokalemic and normotensive on modest amounts of antihyperten-
sive medications.
Discussion
DR. JAMES C. MELBY (Head, Section of Endocrinology and
Metabolism, Evans Memorial Department of Clinical Re-
search, and Department of Medicine, University Hospital, and
Professor of Medicine and Physiology, Boston University
School of Medicine, Boston, Mass.): Primary aldosteronism is a
generic term for disorders in which chronic aldosterone excess
exists independently or semi-independently of the renin-angio-
tensin system, and which results in hypertension and, in most
instances, hypokalemia [1—3]. Estimates of the incidence of
primary aldosteronism in the hypertensive population of the
United States vary from 0.05% to as high as 2%. Most large
studies report an incidence of approximately 0.5% to 1%. The
incidence of primary aldosteronism in the unselected outpatient
hypertensive population of University Hospital is approximate-
ly 0.7% [4]. The peak age distribution of the disorder is between
the third and fifth decades. More women are affected than men,
but the preponderance of women appears to be declining with
the increasing recognition of idiopathic hyperaldosteronism.
Aldosterone overproduction results in hypertension, deple-
tion of potassium and magnesium, and suppression of plasma
renin activity. Hypersecretion of aldosterone is semi-autono-
mous in patients with primary aldosteronism, with the notable
exception of patients with glucocorticoid-remediable hyperal-
dosteronism. The most common adrenal lesion responsible for
primary aldosteronism, as judged by findings at operation, is a
solitary adrenocortical adenoma (aldosteronism-producing ade-
noma [APA]) or Conn's syndrome [5]. Bilateral micro- or
macronodular hyperplasia or idiopathic hyperaldosteronism
(IHA) accounts for the bulk of the remainder of cases. Table I
illustrates the frequency of different types of primary aldoste-
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Table 1. Frequency and therapy of primary aldosteronisma
Frequencya
No.
Treatment'
Literature rrent seriesCu Surgical Medical
Aldosterone-producing adenoma
Idiopathic hyperaldosteronism
Aldosterone-producing carcinoma
Congenital aldosteronism
Glucocorticoid-remediable aldosteronism
(%)
—65
—34
<1
<1
<1
(%)
84.8
13.5
1.2
0.5
0
151
60
2
2
0
149
24
2
1
0
2
36
0
1
0
a Classification data were obtained from surgical specimens.
b Treatment data refer to Boston University experience with 215 patients.
ronism in patients who have been operated on and our total
experience with all forms of primary aldosteronism, whether in
patients who have undergone operation or those who have not.
Pat hophysiology
Aldosterone excess stimulates active sodium transport by the
distal convoluted tubule and collecting duct cells of the kidney.
Enhanced sodium reabsorption results in secretory movement
of potassium and hydrogen ions into the tubular fluid with
consequent potassium depletion and metabolic alkalosis. In
addition, aldosterone exerts a direct stimulatory action on
hydrogen ion secretion in the cortical and medullary collecting
ducts independent of sodium reabsorption [6]. Increased sodi-
um reabsorption by the kidney leads to expansion of the
extracellular fluid volume and elevated total body sodium
content. The expansion of the extracellular fluid volume usually
exceeds 2 liters but is limited by "mineralocorticoid escape."
This term refers to the renal counterregulatory mechanism
involving inhibition of proximal tubular sodium reabsorption.
Aldosterone excess also leads to renal magnesium wastage [7].
Schalekamp, Wenting, and Man In'T Veld have reviewed the
nature of mineralocorticoid hypertension and conclude as fol-
lows [81:
The pathogenesis of mineralocorticoid hypertension is
complicated and results from a series of hemodynamic
alterations including early expansion of intravascular
blood volume and increased cardiac output. After several
months, the total peripheral resistance rises and plasma
volume and cardiac output fall to near normal levels. No
evidence exists that the initial phase of hypervolemia is
essential for the development of sustained hypertension
and the progressive rise in peripheral resistance is incom-
pletely understood at this time.
It is known that experimental magnesium deficiency pro-
duces significant elevation of mean arterial pressure in rats [9].
The magnesium depletion of primary aldosteronism could be
involved in the increased peripheral resistance seen in this
condition. Similarly, experimental potassium deficiency in-
creases systemic arterial resistance [10]. Thus, the hyperten-
sion of primary aldosteronism may be a complex mosaic of
early hemodynamic and sustained electrolyte alterations that
culminate in increased peripheral vascular resistance.
Clinical features and pathologic types of primary
aldosteronism
On clinical grounds, the hypertension of primary aldosteron-
ism is indistinguishable from that which occurs in other disor-
ders. Although it frequently is mild, all the signs and symptoms
of severe, long-standing hypertension have been observed in
some patients. The most consistent and overt biochemical
manifestation of primary aldosteronism is hypokalemia that
results from renal potassium wastage. Spontaneous hypokale-
mia is observed in approximately 80% to 90% of patients with
primary aldosteronism, and easily provokable hypokalemia
occurs in the remainder. By "easily provokable hypokalemia" I
mean the induction of hypokalemia by the administration of
large amounts of sodium chloride for a period of 3 to 5 days.
More than 50% of hypertensive patients with spontaneous
hypokalemia have primary aldosteronism [6].
The degree of hypokalemia seen in patients with primary
aldosteronism is related in part to sodium intake. Sodium
restriction leads to potassium retention and ameliorates hypo-
kalemic manifestations. Conversely, as noted before, sodium
excess promotes renal potassium wastage and can produce
profound hypokalemia. A substantial portion of patients with
spontaneous hypokalemia have no symptoms. Nocturnal poly-
uria and polydipsia are common signs of potassium deficiency.
Neuromuscular manifestations include weakness, paresthesias,
intermittent paralysis, visual disturbances, and frank tetany;
these manifestations can wax and wane with variations in
potassium balance but are extremely rare. Abnormal glucose
tolerance associated with insulinopenia is demonstrable in more
than one-half of the patients; frank type-2 diabetes mellitus can
be precipitated in patients genetically susceptible to this disease
[1].
All forms of primary aldosteronism can be diagnosed by the
demonstration of inappropriately raised blood aldosterone con-
centrations and/or urinary aldosterone metabolite excretion in
the presence of suppressed plasma renin activity; the tests are
diagnostic both with the patient recumbent and erect. When a
diagnosis of primary aldosteronism is virtually certain, the
adrenal lesion must be identified and localized. The importance
of determining the nature and location of the adrenal lesion
cannot be overestimated because the therapeutic approach
differs markedly for the various lesions.
Among patients who have been operated on (Table 1), the
most common adrenal lesion responsible for primary aldoste-
ronism is a solitary adrenocortical adenoma (65% of cases).
These aldosterone-producing adenomas, or APAs, appear more
often on the left than on the right. Most are less than 2 cm in
greatest diameter and have a golden yellow color on the cut
surface. Light microscopy of APAs reveals zona glomerulosa-
type cells, zona reticularis or compact cells, and both large and
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small "hybrid" cells. The "hybrid" cells exhibit features of
glomerulosa and fasciculata cells [11]. This observation is
particularly interesting because Chu and Ulick found that APAs
produce 18-hydroxy-cortisol [121. Cortisol is also secreted by
APA [131. In addition, some APAs have been associated with
diffuse glomerulosa hyperplasia in the nonadenomatous portion
of the gland; ultrastructural studies reveal exclusively glomeru-
losa cells.
The biochemical abnormalities are usually more pronounced
in APA than in other forms of primary aldosteronism. In APA,
aldosterone biogenesis by the adenoma appears to be only
partially autonomous, in that plasma aldosterone concentra-
tions still exhibit a circadian rhythm paralleling plasma cortisol
and ACTH levels [14].
Idiopathic hyperaldosteronism (IHA) due to bilateral micro-
or macronodular hyperplasia of the adrenal cortex, when diag-
nosed prior to surgery, usually is not operated on. Therefore the
experience with bilateral total adrenalectomy for this condition
is limited. In our own series, roughly 14% of patients with IHA
have been operated on, and most had surgery before 1970. The
reason for avoiding surgical therapy in this condition is the
distressingly poor response of the hypertension even to bilateral
total adrenalectomy. In almost every instance, blood pressure
falls but not enough to eliminate the need for antihypertensive
therapy. For such little benefit, the need for the patient with a
bilateral total adrenalectomy for permanent cortisol and, at
times, fludrocortisone replacement, surgical therapy seems
hardly worth it.
Of all patients with primary aldosteronism (those treated
medically as well as surgically), perhaps 40% or more have
IHA. Adrenal glands in patients with IHA exhibit diffuse and
focal hyperplasia of ultrastructurally normal zona glomerulosa
[11]; the hyperplasia usually is accompanied by adrenocortical
nodules. The nodules are similar microscopically and ultra-
structurally to those found in Cushing's syndrome and to the so-
called "nonfunctioning" nodules often found at autopsy in
patients with no evident adrenal disease [111. These nodules
contain lipid-laden cells with electron microscopic features of
clear cells of normal zona fasciculata. Histologically, IHA has
the appearance of a "stimulated" adrenal gland. Because, as
just noted, the nodules resemble very closely those found in
Cushing's syndrome [11, 13], many researchers suspect that an
abnormal secretagogue or an amplifier of angiotensin II may be
produced in this disease.
The nodules in IHA secrete excessive amounts of aldoster-
one, which yields arterial hypertension, potassium and magne-
sium depletion, and suppression of PRA. As noted before, the
biochemical abnormalities often are not as pronounced as in
APA, and suppression of PRA may be incomplete. Activation
of aldosterone biogenesis by small increments in PRA occurs
when patients with IHA stand after prolonged recumbency. In
contrast to patients with APA, there is no parallelism in patients
with IHA between the plasma aldosterone and cortisol concen-
trations [14].
Investigators have identified several potential secretagogues
that might play a role in the genesis of IHA. These include:
angiotensin II, potassium ion, ACTH, serotonin, and, most
recently, an aldosterone-stimulating glycoprotein [15]. Indeed,
in some patients injections of angiotensin LI stimulate an
excessive production of aldosterone. The hyperproduction of
aldosterone in response to angiotensin II has not been explained
in any study thus far. Studies of patients with APA, utilizing
pro-opiomelanocortin—derived peptides, suggest that peptides
near the N terminus might be of significance. For example, Lis
and colleagues demonstrated that the N terminal peptides of
pro-opiomelanocortin could stimulate a dispersed cell prepara-
tion from a human aldosteronoma [16]. The selective stimula-
tion of aldosterone production by a cultured cell preparation of
an adrenal adenoma was not associated with marked increases
in cortisol biogenesis. Similarly, Aurecchia et al demonstrated
that human lysine-y3-MSH (melanocyte-stimulating hormone),
a glycosylated MSH from the 16K fragment (50—76), induced a
dose-dependent aldosterone response in adenomatous and, to a
lesser extent, in nonadenomatous human adrenal tissue in a
patient with APA [171. Lysine-y3-MSH had a significantly
greater effect than did ACTH on adenomatous tissue, and the
effect was selective stimulation of aldosterone as compared to
cortisol. In recent studies from this laboratory [18], we demon-
strated elevated plasma immunoreactive y-melanotropin—stimu-
lating hormone levels in 9 patients with IHA and a low level in
one patient with APA.
In studies by Sen et a! [15], the aldosterone-stimulating
glycoprotein found in the urine appears to have a molecular
weight between 4,100 and 36,000 daltons, and it is excreted
normally in an amount of 150 ng/24 hr. The normal plasma level
of this material is about 70 ngldl. After hypophysectomy,
aldosterone-stimulating glycoprotein disappears completely
from urine. Human pituitary aldosterone-stimulating factor is
found in a concentration of 400 ng/mg of pituitary protein. Of
most importance, however, is that urinary excretion of aldos-
terone-stimulating factor was clearly elevated in idiopathic
hyperaldosteronism; values in the range of 750 to 1000 ng!24 hr
were found [15]. The aldosterone-stimulating glycoprotein in
urine has not yet been completely characterized but may well
turn out to be of great significance as a causative factor in IHA.
Dolan et al recently demonstrated that aldosterone-stimulating
factor is increased in the plasma of patients with IHA, and that
it is not suppressible by dexamethasone [19]. Taken together,
these observations suggest that IHA may be due to altered
pituitary secretory activity.
My colleague, G. T. Griffing, and I administered the angio-
tensin converting enzyme inhibitor enalapril maleate to 3 pa-
tients with IHA and one patient with APA. In the 3 patients
with IHA, this agent normalized blood pressure, restored
potassium balance, increased PRA, and reduced aldosterone
secretion rates, tetrahydroaldosterone excretion, and plasma
aldosterone levels; there was no response in the patient with an
APA (unpublished data). The reduction in aldosterone produc-
tion induced by enalapril maleate suggests that adrenal angio-
tensin II hypersensitivity might play an important role in the
pathogenesis of IHA and that angiotensin converting enzyme
inhibitors like enalapril maleate could be used as therapy for
this disorder.
Idiopathic hyperaldosteronism differs in degree from a poorly
defined entity currently labeled indeterminate or evolving pri-
mary aldosteronism. Approximately 14% of patients with es-
sential hypertension have suppressed PRA levels and plasma
aldosterone values that are inappropriately elevated for the
prevailing level of PRA [4]. In this group of patients, the
average level of plasma aldosterone exceeds 13 ng/dl, and the
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urinary aldosterone secretion is normal or slightly elevated.
Furthermore, when given inhibitors of aldosterone biogenesis,
these patients have an antihypertensive response that is greater
than that in other patients with "essential hypertension."
Adrenocortical carcinoma, a rare cause of primary aldoste-
ronism, has been reported in fewer than 20 patients; the
incidence in large series of primary aldosteronism is about 1%.
The tumors are often large and easily identifiable by excretory
urography. Only 2 of our own series of 215 patients with
hyperaldosteronism have had adrenocortical carcinoma. In
both instances, widespread metastatic disease was present at
the time of diagnosis, and survival was less than 13 months.
Primary aldosteronism in the young, that is, congenital or
juvenile aldosteronism, is rare and similar clinically and patho-
logically to IRA. Usually it is associated with bilateral adrenal
glomerulosa hyperplasia without macronodules, and it can be
familial [201. This lesion is best treated by medical means,
which I will discuss later.
Glucocorticoid-remediable hyperaldosteronism, a rare form
of primary aldosteronism, is associated with bilateral microno-
dular adrenocortical hyperplasia and is characterized by relief
of hypertension and induction of positive potassium balance by
the administration of glucocorticoids. Glucocorticoid-remedia-
ble hyperaldosteronism apparently is due to pro-opiomelano-
cortin—derived peptides that can be suppressed by the adminis-
tration of dexamethasone. It is unlikely that ACTH is the
culpable secretagogue, because cortisol metabolism is unaffect-
ed, but what secretagogue is responsible is not known.
Diagnosis
Primary aldosteronism should be suspected in all hyperten-
sive patients with spontaneous hypokalemia. One also should
suspect it in patients who become hypokalemic almost concur-
rently with the administration of diuretics and who remain so
after diuretics are stopped. Patients with primary aldosteronism
are extremely sensitive to the potassium-wasting effects of
thiazide diuretics but usually exhibit no change in blood pres-
sure. Patients who ingest large amounts of sodium chloride for 3
or 4 days and who become hypokalemic also are suspect [2, 61.
By contrast, in the presence of marked dietary sodium
restriction, patients with primary aldosteronism may exhibit
normal potassium concentrations. In addition, many patients
erroneously are thought to be normokalemic, yet they have
plasma potassium concentrations of or just below 3.5 mEq/liter.
Primary aldosteronism exists in a relatively high percentage of
individuals with initial potassium levels of 3.4 and 3.5 mEq/liter
[2].
Salt-loading can be used as a provocative screening test for
aldosteronism in hypertensive patients with persistently normal
serum potassium levels. We have used this maneuver for years.
Recently, Bravo and colleagues demonstrated that hypokale-
mia, provoked by salt loading, is an important clue to the
diagnosis in a significant percentage of patients with primary
aldosteronism [2]. When aldosterone secretion is suppressed by
salt ingestion in healthy subjects, the distal tubular stimulus to
sodium reabsorption is quickly dissipated, whereas patients
with autonomous aldosterone secretion exhibit a continued
distal tubular sodium reabsorptive activity. Ingestion of sodium
in excess of 200 mEq/day (12 g of salt) for 4 days does not
influence the serum potassium level in the absence of aldoste-
Table 2. Confirmation of primary aldosteronism
Discontinue spironolactone (6 weeks), diuretics (4 weeks), and sym-
pathetic inhibitors (1 week).
Unrestricted sodium intake prior to admission (1 week).
Day i—Admit to hospital on liberal sodium intake (100 mEq/day). Re-
place potassium deficit and keep patient recumbent overnight.
Day 2—Draw supine (8 AM) and 4-hour upright (noon) plasma aldos-
terone, plasma renin activity," and 18-OH-corticosterone lev-
els. Start 24-hour urine collection (8 AM) for aldosterone or
tetrahydroaldosterone b
Day 3—Complete 24-hour urine (0800 hr).
a Plasma renin activity also can be measured following diuretic
stimulation (e.g., furosemide, 40 mg po).
Plasma potassium should be normal before performing this test.
Table 3. Primary aldosteronism. Current series
(176 operated patients)
ronism, whereas in patients with aldosteronism, plasma potassi-
um falls below 3.5 mEq/liter.
The diagnosis of primary aldosteronism can be confirmed
easily by the demonstration of both renin suppression and
aldosterone excess. Before any tests are undertaken, however,
diuretic administration should be discontinued for at least 4
weeks, and spironolactone should be withheld for 6 weeks
(Table 2). Antihypertensive sympathetic inhibitors also should
be discontinued one week before the patient is studied. The
patient is then admitted to the hospital and given a diet
containing more than 120 mEq of sodium daily. Primary aldo-
steronism is confirmed if the urinary excretion of aldosterone
metabolites is increased in the presence of suppressed PRA.
The features of primary aldosteronism in our series of 176
operated patients are shown in Table 3. Several investigators
have employed tests of suppressibility of plasma aldosterone or
aldosterone secretion to gain added diagnostic certainty. In our
laboratory, however, we found that tests using either sodium
loading or mineralocorticoid administration to induce aldoster-
one suppression have little if any advantage over the simple
technique of measuring aldosterone levels after the patient has
Present
Feature (%)
Hypertension
Spontaneous hypokalemia
Easily provokable hypokalemia
Hormonal studies
100
92
8
Increased
(%)
100
84
90
70
97
87
Aldosterone secretion rate
(n = 50—iSO g/24 hr)
Aidosterone 1 8-mon-glucuronide in urine
(n = 2—20 j.tg/24 hr)
Tetrahydroaldosterone glucuronide in urine(n = 12—65 g/24 hr)
"Plasma aldosterone (AM) (n = 2—14)
5Suppressed PRA
BP with spironolactone
a After 1970—50% of patients.
—47% elevated PM.
b After 1966—71% of patients.
Postural plasma aldosterone and l8-OH-corticosterone
levels 90C/
Adrenal iodocholesterol (NP-59) 8O2
Adrenal CT scanning Unknown
Adrenal ultrasound Unknown
Adrenal venous aldosterone sampling
true positives and true negatives
a Accuracy =
total tested populations
Provided both adrenal veins are sampled.
been ingesting a moderately large sodium intake for approxi-
mately one week.
When the results are ambiguous, however, certain additional
maneuvers sometimes can be helpful. Recently, the use of the
"captopril test" has been advocated under these circumstances
[21]. Captopril, an inhibitor of angiotensin converting enzyme,
decreases renin-mediated aldosterone secretion in patients who
do not have primary aldosteronism [22]. Therefore, in normal
individuals who receive captopril, plasma aldosterone levels
fall. In patients with primary aldosteronism, however, captopril
should produce no effect. Preliminary studies using the capto-
pril test in our laboratory have not confirmed these findings. I
would offer the following as a possible explanation for these
discrepant results. Any test carried out during the morning, and
requiring sampling near noon, can be influenced by the circadi-
an variation in plasma aldosterone that occurs in APA. These
tests (such as the captopril test) are invalidated if the finding of
a normal value is taken as evidence against primary aldosteron-
ism; recall that patients with APA can have normal plasma
aldosterone levels during the day.
Another diagnostic approach that has been suggested in-
volves administration of spironoloactone. Spironolactone, a
specific competitive antagonist of aldosterone, neutralizes the
action of aldosterone; it completely relieved hypertension in
approximately 87% of our patients with primary aldosteronism
[61. The molar concentration ratio of spironolactone to aldoster-
one required for inhibition of aldosterone activity, both in vivo
and in vitro, ranges from 100:1 to 1000:1. The response to
spironolactone helps define the best mode of therapy for
aldosteronism but does not help in the differential diagnosis.
Administration of spironolactone in large doses (400 mg) for 3
weeks to patients with hypersecretion of aldosterone and
hypertension reduces the blood pressure significantly in pa-
tients with primary aldosteronism. It does not affect blood
pressure in patients with secondary aldosteronism or in those in
whom hypertension is unresponsive to surgical removal of the
adrenal. Patients with APA who do not respond to spironolac-
tone are not relieved of hypertension by surgical intervention.
The antihypertensive response to spironolactone in primary
aldosteronism is stereotypic. Weight loss of between 2 and 4 kg
occurs within the first 7 to 10 days of therapy, and blood
pressure declines slowly thereafter for the next 10 days. Spiron-
olactone may not, as commonly assumed, act entirely through
reduction in volume, but rather through other mechanisms
including its antikaliuretic and antimagnesiuric effects.
After the diagnosis of primary aldosteronism has been estab-
lished, the cause of the hyperaldosteronism must be deter-
Primary aldosteronism 773
Table 4. Tests for distinguishing APA from IHA and for localizing
primary aldosteronism 80
Accuracy
Adenomas APA) Hyperp/asta (IHA
8AM 12Noon
Supine Uprrght
8 AM
Sup ne
12 Noon
Upright
80
70 70
60 60
50
0
40 400
30 30
3-
20 20
10 10
Fig. 1. P1ama aldosterone levels at 8.00 and at 12:00 noon in
ambulatory patients itith APA and IHA.
mined. The two major forms, APA and IHA. must he distin-
guished, because treatment differs markedly: whereas surgical
adrenalectomy is indicated for APA, medical therapy is general-
ly used for IHA.
To distinguish between unilateral and bilateral adrenal dis-
ease and to localize unilateral APA. one can use a variety of
tests. Table 4 lists these tests and their approximate accuracy.
Many authors advocate adrenal CT scanning and ultrasound
examination for the detection of APA [21. Unfortunately, our
own experience with these procedLires is not very rewarding. In
our experience, adrenal scanning with the currently available
CT technology has yielded an appreciable number of false-
positive and false-negative results: the diagnostic accuracy has
been less than 50%. The aldosteronoma of APA generally
measures less than 2 cm in greatest diameter; such lesions often
are seen only with difficulty by CT scanning. Adrenal ultra-
sound is equally unrewarding when the tumor is small.
The patterns of response of plasma aldosterone and 18-
hydroxy-corticosterone to certain maneuvers provide extreme-
ly useful information for distinguishing APA and IHA. Mea-
surements of plasma aldosterone levels in the supine position
and after 4 hours of upright posture can differentiate APA from
IHA in 90% of patients [141. In patients with APA. plasma
aldosterone levels at noon are significantly lower than those at 8
AM. On the other hand, every patient with IHA whom we have
tested in this way has exhibited a rise in plasma aldosterone
concentration by noon. These results are shown in Figure I.
This difference in the pattern of aldosterone response suggests
that PRA somehow is involved in the IHA response to the
upright posture.
Patients with APA and those with IHA secrete 18-hydroxy-
corticosterone, but the plasma levels are much higher in pa-
tients with APA than in those with IHA 112]. The secretion ratio
of 18-hydroxy-corticosterone to aldosterone normally approxi-
mates 2:1 in vivo and in vitro. Elevation from this normal ratio
has been taken to indicate the presence of a defect in the
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terminal step of aldosterone production at the corticosterone
methyloxidase 11 (CMO-l 1) enzyme step. The secretion ratio of
these two substances does not represent a simple precursor-to-
product ratio because l8-hydroxy-corticosterone is probably
not a direct precursor of aldosterone in vivo. Being independent
products of 18-hydroxylation by corticosterone methyloxidase
type I, I 8-hydroxy-corticosterone and aldosterone are secreted
at remarkably constant relative rates over a wide range of
absolute levels of aldosterone production in normal individuals.
Patients with APA seem to manifest an inefficiency of CMO-ll
enzyme activity and secrete a relative excess of 18-hydroxy-
corticosterone. Figure 2 illustrates that most patients with APA
had 18-hydroxy-corticosterone levels above 100 ng/dl. Figure 3
shows that patients with APA and IHA exhibit the same
differential circadian pattern with 1 8-hydroxy-corticosterone as
with aldosterone. Biglieri and Schambelan are responsible for
most of this work [231, which has been amply confirmed by
others, including our own laboratory [24].
Adrenal imaging with iodocholesterol (131J6/3-iodomethyl-19-
nor-cholesterol) (NP-59) gives a functional assessment of this
disorder and accurately localizes APA in more than 90% of
patients. Because NP-59 accumulates rapidly in the adrenals, it
permits scintigraphy within 5 days of administration. Adrenal
scanning is usually performed, however, after 5 days of dexa-
rnethasone pretreatment to reduce ACTH-induced steroidogen-
esis and thus reduce non-adenomatous uptake of the isotope
[25].
Asymmetrical uptake by the adrenals during suppression
scintiscans is obvious at 5 days after the tracer is injected in
patients with APA. No lateralization is observed in patients
with IHA. Imaging with NP-59 promised to supplant adrenal
vein catheterization for diagnosis and localization in primary
aldosteronism, but we have observed some false negative
Adenomas (APA)
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Fig. 2. Plasma 18-OH-corticosterone and aldosterone levels at 8:00 AM
(recumbent) in patients with APA (0) and IHA(A).
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Fig. 3. Plasma 18-OH-corticosterone levels at 8:00 AM and at 12:00
noon in ambulatory patients with APA and JHA.
results. Adrenal venous aldosterone levels should be measured
when the results of scintigraphy are ambiguous.
Bilateral adrenal venous sampling for measurement of aldos-
terone concentrations is still the most accurate test in the
differential diagnosis of primary aldosteronism. Even so, the
usefulness of the test depends on the proficiency of the radioan-
giographer [26—28]. If the right adrenal vein is entered, the
accuracy of comparative adrenal venous aldosterone levels in
confirming either APA or IHA exceeds 95%. Often, aldosterone
levels on the side of the unilateral adenoma are 20 times (or
more) higher than those in the venous blood from the contralat-
eral gland. Adrenal venography should not be attempted when
one is obtaining specimens for aldosterone measurement; the
excess volume of contrast material required for venography is
associated with a high incidence (10%) of corticomedullary
hemorrhage in our experience.
Normal adrenal venous aldosterone concentration is 100 to
400 ng/dl (Fig. 4). In APA, the ipsilateral adrenal venous
aldosterone concentration is 1,000 to 10,000 ng/dl; more impor-
tant, the ratio of ipsilateral (defined as the site of the lesion) to
contralateral aldosterone concentration is usually greater than
10:1. Correct placement of the catheter in the adrenal vein is
essential. The accuracy of placement can be best evaluated by
obtaining simultaneous ACTH-stimulated, selective adrenal
venous cortisol levels. An aldosterone ratio greater than 10:1 in
the presence of a symmetrical ACTH-induced cortisol response
is diagnostic of an aldosterone-producing adenoma.
Treatment
Unilateral adrenalectomy is highly successful in treating APA
and is best carried out via a posterior incision made through the
bed of the twelfth rib. One year postoperatively, 70% of the
patients are normotensive, but 5 years postoperatively, only
53% remain normotensive (Table 5). The restoration of potassi-
um balance is permanent, however. In the treatment of IHA,
bilateral adrenalectomy relieves hypertension in only one-third
of patients and has been all but abandoned (Table 5). As I noted
before, not only are the results far from ideal, but substituting
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Fig. 5. Effect of amiloride, 20 mg/day, on blood pressure and plasma
potassium levels in a patient with APA.
the problems of adrenal insufficiency for those of primary
aldosteronism is often an unwelcome tradeoff.
The new potassium-sparing agent, amiloride, is dramatically
effective in restoring potassium balance in patients with primary
aldosteronism (Fig. 5) [29—31]. Amiloride, in doses of 10 to 20
mg/day, restores potassium balance in most patients with APA
and IHA; spironolactone is also effective in restoring potassium
balance. Neither agent, however, restores blood pressure levels
to normal in all patients. Amiloride reduces blood pressure in all
patients, but only 30% to 40% of patients become normotensive
when given only amiloride. Recently we have been using the
angiotensin converting enzyme inhibitor enalapril maleate with
great success to both control blood pressure and restore potas-
sium balance in patients with IRA. This suggests that IHA is
somehow angiotensin II dependent through a mechanism not
yet understood.
In adrenal cancer, cisplatin is an effective cytotoxic agent
against several forms, but high doses are necessary and re-
sponses sometimes do not occur until months after the begin-
ning of therapy; these responses often are sustained, however.
Table 5. Percentage of patients surgically treated for primary
aldosteronism who remain normotensive
1 year 5 years 10 years
Unilateral adrenalectomy for APA 70 53 56
Bilateral adrenalectomy for IHA 32 30 34
We have used cisplatin therapy in 4 patients with adrenocortical
carcinoma, but we have not had an opportunity to use this form
of therapy in patients with aldosterone-producing adenocortical
carcinoma [32].
Questions and answers
DR. SEYMOUR REICHLIN (Chief, Endocrinology Division,
Department of Medicine, NEMC): Dr. Melby, thank you for an
excellent analytic review of aldosteronism. Let me begin the
discussion period by asking, why operate at all if you have a
drug such as amiloride that is inexpensive, easy to use, and
effective?
DR. MELEY: I agree that there is controversy about whether it
is necessary to remove, by unilateral adrenalectomy, tumors in
patients with aldosterone-producing adenomas. However, the
morbidity of the operation is very low, particularly when the
surgeon uses the posterior approach through the bed of the
twelfth rib, as does Dr. Egdahl and did Dr. Smithwick before
him at our institution; the mortality and morbidity with this
procedure are extremely small. I believe that most endocrinolo-
gists in this field would opt for surgery if the tumor is unilateral
and can be localized, because hypokalemia is reversed perma-
nently and hypertension disappears in a high percentage of
patients (Table 5).
DR. JOHN T. HARRINGTON: What about the long-term follow-
up of these patients treated with amiloride? How long have you
treated these patients medically?
DR. MELBY: We know the data at 7.5 years. Those patients
who remained normotensive through the first year are still
normotensive, but only 30% of the entire group remain normo-
tensive. All patients do have a reduction in systolic pressure.
DR. IVOR JACKSON (Division of Endocrinology, NEMC). I am
interested to know whether the effect of amiloride is mediated
via some unique pharmacologic process. In other words, does
amiloride have a qualitatively different action from that of
triamterene?
DR. MELBY: There probably is no difference in action at the
renal level. However, triamterene is metabolized by the liver
and amiloride is not. In our experience with patients with
primary aldosteronism, amiloride is between 30 and 40 times as
potent as triamterene in restoring plasma potassium values.
Triamterene also is not as effective a saluretic as amiloride.
DR. MARK MOLITcH: (Division of Endocrinology, NEMC):
You suggested that adrenal venography not be done because of
the risk of adrenal infarction. Have you tried that technique
therapeutically or tried embolization of an adrenal tumor?
DR. MELBY: No, we have not. In the joint experience of
University Hospital and New England Medical Center (unpub-
lished data), we have had a 10% to 15% incidence of cortico-
medullary adrenal hemorrhage when we attempted detailed
venography of the adrenals by using positive-pressure injection
of contrast material into the glands. Corticomedullary hemor-
HA APA
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rhage can be avoided by gentle manipulation of the catheter and
minimal dye injection. In any event, corticomedullary hemor-
rhage has not achieved cure in either APA or IHA.
DR. NIcoLAos E. MADIAS: I have two questions. First, why
does hypertension persist in some 50% of the patients with
aldosterone-producing adenomas following successful opera-
tion? Do you have an explanation other than the possibility of
coincidental essential hypertension and/or nephrosclerosis from
long-lasting hypertension? Second, why does prolonged admin-
istration of large doses of deoxycorticosterone acetate or aldos-
terone to humans ingesting a normal diet produce only a
marginal increase in plasma bicarbonate concentration, as
opposed to the frank hyperbicarbonatemia of the clinical entity?
DR. MELBY: The incidence of essential hypertension in the
United States is very high—in the 15% range. Dr. Robert W.
Wilkins, one of the great authorities on the natural history of
hypertension, believed that the association of primary aldoste-
ronism and essential hypertension was perhaps coincidental. I
don't know. It may well be that salt sensitivity is genetic and
that this salt sensitivity is responsible for the way an individual
responds to mineralocorticoids over a long period. For exam-
ple, the Dahi rat has pure strains that are sensitive to salt and
pure strains that are resistant to salt. By the way, the salt-
sensitive rat makes more mineralocorticoid in the form of 18-
hydroxy-li-deoxycorticosterone (18-OH-DOC). You may be
right that the hypertension and the hyperaldosteronism are
coincidental diseases, but the steroid may induce some change
in those salt-sensitive individuals that makes them permanently
hypertensive.
DR. JEROME P. KASSIRER: You haven't answered Dr. Ma-
dias' second question. He wondered why there is a discrepancy
between naturally occurring primary aldosteronism and artifi-
cially induced aldosteronism in the extent of the metabolic
alkalosis. When we gave normal individuals ingesting a small
diet daily injections of 1000 jg of aldosterone in divided doses
around the clock for 3 months, their blood pressures did rise,
but plasma bicarbonate concentrations increased 2 or 3 mEq/
liter and their serum potassium concentrations fell only slightly
[331. Although the direction of change of plasma bicarbonate
and potassium were consistent with that seen in primary
aldosteronism, the magnitude was not.
DR. MELBY: As you know, you used aldosterone acetate that
I provided in those studies. The problem is that the clearance of
aldosterone acetate might have been altered. The production
rate of aidosterone may have to be steady and persistent to
mimic all of the features of primary aldosteronism. Aldosterone
levels in the adrenal venous effluent are very constant in
patients with primary aldosteronism due to an adenoma. With
cortisol, the levels are much more variable. One can produce
severe hypertension in rats given aldosterone by osmotic mini-
pump. Komanicky and I have published these studies [341.
Aldosterone has been the most potent of the mineralocorticoids
with the possible exception of the 19 nor-steroids.
DR. MADIAS: Did the bicarbonate rise?
DR. MELBY: Yes.
DR. KASSIRER: How much?
DR. MELBY: I don't know, but not greatly.
DR. KASSIRER: I find, it hard to accept the view that the
regimen of aldosterone administration that we used was ineffec-
tive because the subjects experienced a gain in weight, a rise in
blood pressure, and a fall in serum potassium. That sounds like
hyperaldosteronism.
DR. MELBY: But bicarbonate levels are not greatly elevated
in most patients with primary aldosteronism.
DR. KASSIRER: In fact, we reviewed more than 100 patients in
the literature with primary aldosteronism, eliminating all who
might have any other acid-base or electrolyte disturbance. We
found that about 40% of patients with primary aldosteronism
have plasma bicarbonate concentrations greater than 35 mEq/
liter and 14% have plasma bicarbonate concentrations of 40
mEq/liter or more [33].
DR. MELBY: I know that but we see an enormous variation in
plasma bicarbonate, and I usually neglect mentioning it because
of this variation.
DR. JAMES STROM (Acting Chief of Nephrology, St. Eliza-
beth's Hospital, Boston): I saw a patient recently with a 20-year
history of hypertension that had just accelerated. There was a
history of diuretic-induced mild hypokalemia. I obtained
"screening" plasma renin and aldosterone levels without stop-
ping beta-blockers or vasodilators because his hypertension
was severe. The renin was unmeasurable and the aldosterone
level was elevated. A probable aldosterone-secreting tumor was
found by a CT scan of the adrenals. The questions I want to ask
are: First, how frequently is the plasma renin unmeasurable in
patients with primary aldosteronism who are taking beta
blockers? Second, is plasma renin a reasonable screening test
for primary aldosteronism in patients taking diuretics?
DR. MELBY: The answer to your first question is infrequent-
ly; beta blockers reduce primarily the upright posture renin, and
usually by no more than 25% to 40%. In answer to your second
question, I think an unmeasurable renin in a patient receiving
diuretics is diagnostic of primary aldosteronism.
DR. DAVID CAHAN (Chief of Nephrology, Faulkner Hospital,
Boston): There is a considerable overlap of plasma renin values
in patients with primary aldosteronism or with primary hyper-
tension, and there is also a significant number of patients with
primary aldosteronism without obvious hypokalemia. What
outpatient workup do you recommend as the simplest, most
cost-effective method of screening? How accurate is such
testing?
DR. MELBY: One can construct a nomogram with plasma
renin and plasma aldosterone levels, if sodium intake is be-
tween 100 and 150 mEq/day and an inappropriate level of
aldosterone for plasma renin can be established. In the hyper-
tensive population, there is a group of patients who may well
have "evolving" primary aldosteronism. Using the nomogram,
14% of patients with hypertension have levels of aldosterone
that are too high and plasma renin levels that are very low. The
question is whether these patients have abnormally excessive
aldosterone in the sodium surfeit state. These patients are
usually not spontaneously hypokalemic, but they are very
sensitive to diuretics.
DR. TIMOTHY STRYKER (Fellow, Division of Endocrinology,
NEMC): What is the diagnostic utility of a saline suppression
test?
DR. MELBY: Tests that depend on some hours between
measurements can be misleading. A fall in the plasma aldoster-
one level to less than 10 ng/dl following a 2 liter infusion of
saline in 2 hours is supposed to exclude primary aldosteronism.
However, a few patients with APA have normal aldosterone
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levels in the afternoon, and that can occur as early as 10 AM.
The aldosterone levels fall dramatically during the day in
patients with primary aldosteronism due to an adenoma: aldos-
terone levels then increase gradually during the night.
DR. RONALD PERRONE (Attending P/tvsician, Division of
Nephro/ogv, NEMC,i: Is there any role for the 19-nor steroids
or any other steroids in either hyperaldosteronism or low-renin
hypertension?
DR. MELBY: We have reported excess excretion of 19-nor-Il-
deoxycorticosterone oxycorticosterone in patients with pri-
mary aldosteronism [35—37]. Nearly as potent as aldosterone.
19-nor-I 1-deoxy-corticosterone also can produce hypertension.
In patients with low-renin hypertension, the story isn't in.
There are a few who have very high levels of the 19-nor
steroids.
DR. MADIAS: Do you have any insights into why patients with
primary hyperaldosteronism are often mildly hypernatremic?
DR. MELBY: No. Polyurii and polydypsia do occur with this
condition. We have looked at rats given aldosterone using the
Alzet minipump. The rat given aldosterone becomes polydypsic
before becoming hypernatremic, polyuric, and hypokalemic.
DR. JAcKsON: Could you say something about glucocorti-
cold-suppressible hyperaldosteronism? Is the correction of the
hypertension solely due to suppression of ACTH. another
glycopeptide. or something else? Also, do you incorporate a
dexamethasone suppression test in the routine studies of pa-
tients with suspected primary hyperaldosteronism?
DR. MELBY: I believe that the modulation of the blood
pressure is due to another non-ACTH POMC-derived peptide
or to something that dexamethasone suppresses as a result of
inhibiting POMC messenger RNA. I say this because ACTH
levels are not elevated in this condition. Immunoreactive y-
melanotropin—stimulating hormone may be elevated, however.
No, I do not perform the dexamethasone suppression test
routinely. The condition is so rare, I don't believe it's worth
doing regularly.
Reprint requests to Dr. J. Me/by ection of L'ndocrino/ogv and
Metabolism, University Hospital, Room E-215, 75 East Nemm'to,, Street,
Boston, Massachusetts 02/18, (ISA
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